The articles behind the explanations

Find the paper that matches the claim. The notes below explain what each source can help you understand.

Some sources report experiments; others review earlier work. A review connects findings without adding another group trying a treatment. These notes keep that difference in view.

Most links open a PubMed abstract, with routes to the full article. Journal access may be needed. The FDA sources explain safety and compounding questions.

Thymulin and zinc

Zinc removal and restoration in a thymulin cell assay

Dardenne M and colleagues. Proc Natl Acad Sci U S A (1982).

Removing zinc stopped thymulin's activity in a cell test; adding it back restored it. This explains the zinc connection, not a human treatment benefit.

How zinc binds to thymulin

Dardenne M and colleagues. Met Based Drugs (1994).

A review of zinc binding and thymulin. Helpful background on the attached mineral, rather than another trial of a thymulin treatment.

Thymulin activity during human zinc deficiency

Prasad AS and colleagues. J Clin Invest (1988).

Low blood thymulin activity recovered with zinc in people with mild zinc deficiency. This wasn't a trial of thymulin treating an illness.

Thymulin gene delivery in mice with allergic asthma

da Silva AL and colleagues. Sci Adv (2020).

Mice with allergic asthma received genetic instructions to make thymulin, and lung damage improved. The gene-therapy method is part of that finding.

Thymulin physiology and hormone-system research

Reggiani PC and colleagues. Curr Pharm Des (2014).

A review of thymulin, hormone systems and rodent gene therapy. It broadens the biology without settling human safety or treatment benefits.

KPV and delivery

Alpha-MSH and its related small peptides

Brzoska T and colleagues. Endocr Rev (2008).

KPV shows anti-inflammatory activity without alpha-MSH's skin-darkening action in lab research. This review explains the relationship; it doesn't establish safety.

KPV uptake and bowel inflammation in cells and mice

Dalmasso G and colleagues. Gastroenterology (2008).

KPV entered bowel cells through PepT1, a transport protein, and reduced inflammatory signalling. The paper includes mice; human cells aren't people receiving treatment.

Coated KPV particles in a mouse colitis experiment

Xiao B and colleagues. Mol Ther (2017).

Coated KPV particles inside a gel helped deliver it to inflamed bowel tissue in mice. The protective materials belong in the explanation.

Safety and regulatory reading

FDA safety-risk listings for bulk compounding substances

U.S. Food and Drug Administration.

The FDA page current as of April 22, 2026 lists KPV as nominated but withdrawn. That isn't clearance or permission to compound. The safety concern remains beside the entry.

FDA review of KPV-related bulk drug substances

U.S. Food and Drug Administration.

The FDA found no human KPV clinical studies or exposure data, plus major gaps in animal safety testing. The review explains why favourable inflammation findings don't establish human safety.

Looking for a particular finding? Follow its link on the thymulin, KPV or comparison page. If our description gets a paper wrong, the contact page explains how to send a correction.